ArticleAmerican journal of translational research2025
Effect of tirofiban arterial injection on neurological and endothelial function in acute ischemic stroke patients beyond the thrombolysis time window.
Article in American journal of translational research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo evaluate the efficacy and safety of arterial tirofiban injection in patients with acute ischemic stroke (AIS) beyond the thrombolysis time window.
methodsIn this retrospective single-center study, clinical data were analyzed from 230 AIS patients treated at the First Hospital of Yulin between July 2021 and January 2023. Patients were divided into two groups: the observation group (n=102) treated with tirofiban combined with dual antiplatelet therapy, and the control group (n=128) that received dual antiplatelet therapy alone. Post-treatment follow-up evaluated neurological function, endothelial function, and safety using the National Institutes of Health Stroke Scale (NIHSS), modified Rankin Scale (mRS), and Barthel Index (BI). Endothelial function was assessed by measuring levels of endothelin-1 (ET-1), nitric oxide (NO), and von Willebrand factor (vWF). Baseline characteristics, treatment protocols, and complications were analyzed to ensure the reliability and scientific rigor of the results.
resultsCompared to the control group, the observation group demonstrated significant improvements in NIHSS, mRS, and BI scores, indicating enhanced neurological function and self-care ability. Endothelial markers (ET-1, NO, and vWF) also significantly improved in the observation group, suggesting a beneficial effect on endothelial function. The overall efficacy rate at 90 days was 86.72% in the observation group, significantly higher than the 74.50% in the control group (P<0.05). In terms of safety, there were no significant differences in the incidence of adverse events between the two groups, indicating that tirofiban is well-tolerated. Multivariate analysis identified age, treatment protocol, and baseline NO levels as independent factors affecting the 90-day prognosis, underscoring the importance of individualized treatment strategies for AIS patients.
conclusionArterial injection of tirofiban significantly improves neurological and endothelial function in AIS patients beyond the thrombolysis time window while maintaining a favorable safety profile. These findings support the use of tirofiban in patients who are ineligible for intravenous thrombolysis or endovascular treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.